The pharmaceutical sector generally offers defensive characteristics, steady cash flows, and reliable dividend yields that make it an attractive allocation for conservative and balanced investment portfolios across various economic cycles. Healthcare demand remains resilient during downturns due to ongoing medical needs and aging global populations. However, individual stock performance varies widely based on patent expirations, clinical trial outcomes, regulatory hurdles, and pricing pressures, requiring thorough fundamental research rather than treating the entire industry as a single uniform buy.